A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1.

Chen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, Song W, Li X, Li L, Du Z, Jia L, Zhou L, Li W, Hoffman AR, Hu JF, Cui J. · 2018

Read A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. by Chen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, Song W, Li X, Li L, Du Z, Jia L, Zhou L, Li W, Hoffman AR, Hu JF, Cui J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6290540.txt.

Introduction

Chen and co-authors report a new circular RNA that helps breast cancer spread. The work appeared in Genome Biology. The team focused on FLI1, a gene that can drive cancer growth. Staining tests showed FLI1 at high levels in advanced, spreading tumors.

They found a circular RNA built from parts of the FLI1 gene. They named it FECR1. Adding FECR1 made breast cancer cells more invasive in lab tests. The RNA pulls in an enzyme that strips methyl marks from the FLI1 promoter. It also lowers a second enzyme that keeps those marks in place. This loop switches FLI1 on and feeds tumor growth and spread.

Catalog record

CREATORChen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, Song W, Li X, Li L, Du Z, Jia L, Zhou L, Li W, Hoffman AR, Hu JF, Cui J.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6290540

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1 By Naifei Chen, Gang Zhao, Xu Yan, Zheng Lv, Hongmei Yin, Shilin Zhang, Wei Song, Xueli Li, Lingyu Li, Zhonghua Du, Lin Jia, Lei Zhou Published in: Genome Biology DOI: 10.1186/s13059-018-1594-y ABSTRACT Background Friend leukemia virus integration 1 (FLI1), an ETS transcription factor family member, acts as an oncogenic driver in hematological malignancies and promotes tumor growth in solid tumors. However, little is known about the mechanisms underlying the activation of this proto-oncogene in tumors. Results Immunohistochemical staining showed that FLI1 is aberrantly overexpressed in advanced stage and metastatic breast cancers. Using a CRISPR Cas9-guided immunoprecipitation assay, we identify a circular RNA in the FLI1 promoter chromatin complex, consisting of FLI1 exons 4-2-3, referred to as FECR1.Overexpression of FECR1 enhances invasiveness of MDA-MB231 breast cancer cells. Notably, FECR1 utilizes a positive feedback mechanism to activate FLI1 by inducing DNA hypomethylation in CpG islands of the promoter. FECR1 binds to the FLI1 promoter in cis and recruits TET1, a demethylase that is actively involved in DNA demethylation. FECR1 also binds to and downregulates in trans DNMT1, a methyltransferase that is essential for the maintenance of DNA methylation. Conclusions These data suggest that FECR1 circular RNA acts as an upstream regulator to control breast cancer tumor growth by coordinating the regulation of DNA methylating and demethylating enzymes. Thus, FLI1 drives tumor metastasis not only through the canonical oncoprotein pathway, but also by using epigenetic mechanisms mediated by its exonic circular RNA. Electronic supplementary material The online version of this article (10.1186/s13059-018-1594-y) contains supplementary material, which is available to authorized users. INTRODUCTION The ETS gene family of transcription factors share a common ETS DNA binding domain responsible for sequence-specific DNA recognition on target promoters, and they play critical roles in controlling cell proliferation, transformation, apoptosis, and tumorigenesis [1–3]. Among the ETS family members, Friend leukemia virus integration 1 (FLI1) was first identified as a proto-oncogene activated by proviral integration in F-MuLV-induced erythroleukemias [4]. FLI1 is preferentially expressed in hematopoietic cells and tissues, where it regulates hematopoietic stem cell self-renewal and differentiation [5, 6]. Aberrant expression of FLI1 may act as a critical driver in the development of hematological malignancies [7–10]. Overexpression of FLI1 in erythroblasts causes inhibition of differentiation and ultimately the development of pre-T cell lymphoblastic leukemia/lymphoma [11]. In addition to erythroleukemia, the aberrantly deregulated FLI1 is also associated with other hematological malignancies, including pre-T cell lymphoblastic lymphoma, acute myeloid leukemia, and B cell lymphomas [1]. Recent studies have shown that FLI1 is also aberrantly expressed in some solid tumors, including Ewing sarcoma [12, 13], metastatic melanomas [14], nasopharyngeal carcinoma [13], and non-Ewing soft tissue tumors [15]. A series of clinical studies from our lab showed that FLI1 is overexpressed in breast cancers [16] and lung cancers [17]. In patients with breast cancer, expression of FLI1 is strongly correlated with advanced stage, poor differentiation, and lymph node metastasis. In highly metastatic human breast cancer cells, knockdown of FLI1 significantly attenuated tumor metastasis through the Rho GTPase pathway [16]. In non-small cell lung cancer, the FLI1 expression score is associated with the stage of SCLC. In these cells, FLI1 promoted tumor metastasis by activating the miR-17-92 cluster family [17]. However, little is known about the molecular mechanisms underlying the aberrant activation of FLI1 in these solid tumors. In this study, we harnessed a novel CRISPR Cas9-guided promoter immunoprecipitation (CasIP) assay to identify the molecular components that interact with the FLI1 promoter. We hypothesized that these components might actively participate in the control of FLI1 in the development of breast cancers. Using this CasIP assay, we identified FECR1, a FLI1 exonic circular RNA that binds to the FLI1 promoter and epigenetically activates FLI1 in breast cancer cells. RESULTS CasIP identifies a novel FLI1 exonic circular RNA To determine the role of FLI1 in breast cancer, we first examined its expression in tumor samples collected from patients with breast cancer. Using immunohistochemical staining, we found that FLI1 was significantly activated in breast tumor tissues as compared with adjacent normal tissues (Fig. 1a, b; red arrows). There was also a relatively high abundance of FLI1 in breast cancer tissues associated with metastases (Additional file 1: Figure S1A-S1B) and in advanced stages (Additional file 1: Figure S1C-S1D).Fig. 1Identification of FLI1 circular RNA by Cas9IP. a Overexpression of FLI1 in breast cancer tissues. FLI1 expression was quantitated by immunohistochemical staining and was evaluated as the expression score. **p < 0.01 in breast carcinoma tissues as compared with their adjacent tissues. b High expression of FLI1 in carcinoma as compared with adjacent tissues. Red arrow: dark brown immunohistochemical staining of FLI1 oncoprotein. c CRISPR Cas9-guided chromatin immunoprecipitation (CasIP). Cas9, CRISPR Cas9; FLI1 gRNA, Cas9 guiding RNAs that target the FLI1 promoter. Cas9 binds to the FLI1 promoter through a mechanism of base pairing between the gRNA and target DNA. After fixation, the Cas9-FLI1 promoter chromatin complex was immunoprecipitated by an anti-Cas9 antibody. The CasIP-captured RNAs were sequenced to identify the RNA components that regulate the gene activity in breast cancers. d Identification of FLI1 circular RNA by CasIP. In the FLI1 Cas9-gRNA cassette vector, two Cas9 gRNAs are transcribed by U6 and H1 promoters, respectively, and guide Cas9 to the FLI1 promoter. The CasIP sequencing identifies a novel FLI1 exonic circular RNA that interacts with the gene promoter. e Enrichment of FECR1 in the FLI1 promoter. After CasIP, the captured RNAs were reverse transcribed to quantitate the abundance of FECR1 in the Cas9-captured promoter complex. M, 100 bp marker; IgG, ChIP with antibody control; Cas9, ChIP with anti-Cas9 antibody; nAb, the ChIP negative control, in which the anti dCas9-FLAG antibody was replaced by the equal amount of albumin protein To identify the molecular components that aberrantly regulate FLI1 in breast cancer, we utilized a novel CasIP approach to immunoprecipitate the FLI1 promoter chromatin complex (Fig. 1c). We hypothesized that identification of the components that participate in the formation of the chromatin interaction network in the gene promoter might suggest mechanisms underlying the aberrant FLI1 activation in tumors. We constructed a lentiviral vector containing the catalytically inactive CRISPR Cas9 (dCas9) and two FLI1 promoter gRNAs (Fig. 1d and Additional file 1: Figure S2) and transfected it into MDA-MB231 breast cancer cells. After puromycin selection, stable cells were treated with 1% formaldehyde to fix the dCas9-gRNA-FLI1 promoter chromatin complex. To avoid RNA degradation, we performed an in situ reverse transcription to convert chromatin RNAs into cDNA with biotin-dCTP. The FLI1 chromatin complex was immunoprecipitated with an anti Cas9-FLAG antibody. After reversing the crosslinks, the FLI1 promoter-associated cDNAs were separated from genomic DNAs with streptavidin beads and were cloned into pJet vector for sequencing. Through this Cas9 immunoprecipitation sequencing, we identified a novel FLI1 circular RNA that interacted with the FLI1 promoter that we refer to as FECR1 (FLI1 exonic circular RNA). The interaction of FECR1 with the FLI1 promoter was confirmed using CasIP PCR. We found that FECR1 was enriched in breast cancer cells that were transfected with Cas9-FLI1 gRNAs (Fig. 1e, top panel, lane 2). No CasIP signals were detected in cells that were transfected with Cas9 control gRNAs (gCT, middle panel). Neither

Read the complete text